For description of this study, please see my thread from when we first posted the paper in @medrxivpreprint in March 👇🏽 One of the deepest immune profiling that captures reinfection in a longitudinal manner. (2/)
In a nutshell, this transplant patient had, prior to reinfection;
• Huge levels of circulating innate and adaptive cytokines (chronic inflammation)
• Very few naive lymphocytes & dominant exhausted T cells
• Elicited poor and transient neutralizing Ab responses
(3/)
We are delighted to have this study published in the Journal of Infectious Diseases @IDSAInfo!
1) mRNA vaccines (2 shots) induce robust antibodies & T cells to SARS-CoV-2 2) certain mutations in VOC ⬆️ Ab escape 3) prior infection + 2 mRNA shots produce very high neutralizing Ab against most VOC 🦠(1/)
An important new study looks at how COVID vaccines impacts symptoms in #LongCovid patients. @thitran3’s team used data from ComPaRe long COVID cohort to emulate a target trial (1:1 matched vax:unvax) measuring outcome at 120 days after baseline. (1/)
The study found that the rate of complete remission from long COVID symptoms doubled in vaccinated patients compared to unvaccinated long COVID patients. Wow, vaccines appear to be helping long haulers with recovery 👏🏼 (2/)
In addition, disease impact of long covid on patients’ lives were significantly reduced (symptoms improved) in vax group (long COVID IT score of 24.3) compared to unvax group (IT score of 27.6). (3/)
I am very proud of @marioph13, @peowenlu and @ValterVSM for participating in #scicomm. They explained viral plaque assay, flow cytometry and ELISA to news reporter from WAPA TV 🇵🇷 via @dacolon
Here is @Marioph13 explaining viral plaque assay en español 🤩 (too bad his excellent explanation did not make it into the video clip) (2/)
Here, @ValterVSM explains ELISA, how it can detect levels of antibodies in a person, and what antibody levels mean for protection against SARS-CoV-2 VOCs 💪🏼 (3/)
Excited to share our work by @BenIsraelow et al published today. We asked what are the roles of antibodies vs. T cells in controlling primary infection, reinfection, and vaccine-mediated protection? (1/n)
First, we asked if B cells are needed to control primary infection. We used muMT mice (devoid of B cells) transduced with AAV-hACE2. These mice had only a slight delay in viral clearance. Thus B cells are not necessary for controlling primary SARS-CoV-2 infection. (2/n)
However, in mice that have neither T cells nor B cells (RAG-/-), SARS-CoV-2 persisted with no sign of clearance. Thus, innate immunity is insufficient, and adaptive immunity is required to control primary infection. (3/n)
In this new Neuroview in @NeuroCellPress, I discuss "How COVID-19 has transformed my science”. Recounting my personal journey of how I responded to the pandemic, and how the pandemic has transformed the way I do science. Some lessons learned. (1/n)
Glad to highlight my amazing colleagues who made team science possible. The Yale IMPACT team, Albert Ko, @SaadOmer3@NathanGrubaugh@ShelFarFar @CharleszYaleMed @EllenFoxman Allison Nelson & many others. @wade_schulz opened my 👀 to the power of data science (2/)
Yale IMPACT team made quite a contribution on our understanding of viral transmission, detection, disease and immunology behind COVID-19. @EricTopol says it best👇🏽 (3/)
How do the various mutations within the SARS-CoV-2 variants impact vaccine-induced immunity? The amazing @carolilucas@VogelsChantal@InciYildirim11 led this study with with help from others to tackle this question - using 18 CoV-2 variants. (1/n)
The study was designed to measure antibody and T cell immunity from people who were previously infected or not infected with SARS-CoV-2, before and after the 1st and 2nd doses of mRNA vaccines. Amazing effort by @InciYildirim11@SaadOmer3 (2/n)
Antibodies to the ancestral S1 and RBD were induced in both prev. infected and uninfected vaccinees. S/S1/RBD-specific IgG levels in response to vaccination were significantly higher in the previously infected compared to uninfected, as reported by others. (3/n)